A Study Tislelizumab in Combination With Chemotherapy Versus Chemotherapy in Advanced Lung Cancer.
Last updated on July 2021Recruitment
- Recruitment Status
- Active, not recruiting
- Estimated Enrollment
- 342
Summary
- Conditions
- Non -Small Cell Lung Cancer
- Type
- Interventional
- Phase
- Phase 3
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 75 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT03594747
- Collaborators
- Not Provided
- Investigators
- Principal Investigator: Jie Wang, MD Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Get Well Soon